

## Special Issue

# Advances in Treatments for Hutchinson-Gilford Progeria Syndrome

### Message from the Guest Editor

Hutchinson–Gilford Progeria Syndrome is an ultra-rare “premature aging” disease. A de novo point mutation in the prelamin A gene results in an aberrant splicing and causes the accumulation of the spliced shortened form, progerin, at the nuclear envelope. Progerin is toxic and causes distorted nuclei and aging-related phenotypes, and death in the teenage years from cardiopulmonary arrest or cerebral infarction. Although they appear healthy at birth, most children with Progeria begin to display premature aging within the first year of life. It is a milestone for the field that Farnesyltransferase lonafarnib was approved as the first targeted therapy for children with HGPS, but the effect is modest. Therefore, it is urgent to understand the precise mechanisms of HGPS pathology and to develop better treatments for children suffering from HGPS. This Special Issue will examine new therapeutics for HGPS treatment, novel model mouse systems to help to prove progerin toxicity, methods to advance a better understanding of HGPS cells or progerin protein, organ-specific pathology of HGPS, modulation of cytokine signaling in HGPS, and genome structure in HGPS.

---

### Guest Editor

Prof. Dr. Bumjoon Park  
Department of Molecular Biology, College of Natural Science, Pusan National University, Busan 46241, Republic of Korea

---

### Deadline for manuscript submissions

closed (31 October 2023)



## Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/si/149796](https://mdpi.com/si/149796)

*Cells*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cells@mdpi.com](mailto:cells@mdpi.com)

[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)





# Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)



## About the Journal

### Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

---

### Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,  
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,  
Copenhagen, Denmark

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).